Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2023-04-20 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
关于召开2022年年度股东大会通知的补充说明
AGM Information Classification · 95% confidence The document is a detailed notice and supplementary explanation regarding the convening of the 2022 Annual General Meeting (AGM) of 河南新天地药业股份有限公司. It includes information about the meeting agenda, voting procedures, proxy forms, meeting logistics, and related resolutions. The document references the 2022 annual report and other reports to be discussed at the AGM but does not contain the reports themselves. It is primarily an announcement and detailed notice about the AGM and its procedures, not the actual annual report or financial statements. Therefore, it fits the category of AGM Information (AGM-R). The document length (7960 characters) and content confirm it is a full AGM notice rather than a brief announcement or a report publication announcement.
2023-04-20 Chinese
关于使用闲置自有资金购买结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Henan Xintiandi Pharmaceutical Co., Ltd. regarding the use of idle own funds to purchase structured deposits. It details the investment amount, product type, expected returns, risk factors, and risk control measures. The document is relatively short (2109 characters) and focuses on a specific financing activity involving the company's own funds. There is no indication of comprehensive financial statements, quarterly or annual results, or management discussion of financial performance. It is not a report but an announcement about a capital management activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-04-13 Chinese
关于使用部分闲置募集资金购买结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Henan Xintiandi Pharmaceutical Co., Ltd. regarding the use of part of idle raised funds to purchase structured deposits. It details the approval by the board and supervisory committee, the investment amount, risk control measures, and compliance with regulatory requirements. The document is relatively short (2649 characters) and focuses on a specific financing activity involving the use of idle raised funds for cash management. It does not contain comprehensive financial statements or detailed financial performance data. It is not a full financial report but an update on capital usage and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-04-13 Chinese
关于控股子公司使用闲置自有资金购买结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Henan Xintiandi Pharmaceutical Co., Ltd. regarding the use of idle funds by its controlling subsidiary to purchase structured deposits. It details the investment amount, expected returns, risk factors, and risk control measures. The document is short (1418 characters) and focuses on a specific financing activity related to the company's capital management. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. The content fits the category of Capital/Financing Update (CAP), as it informs about the company's financing activity involving structured deposits.
2023-04-07 Chinese
关于使用闲置自有资金购买结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Henan Xintiandi Pharmaceutical Co., Ltd. regarding the use of idle funds to purchase structured deposits. It details the investment amount, expected returns, risk factors, and risk control measures. The document is short (1307 characters) and focuses on a specific financing activity involving the company's own funds. It does not contain financial statements or comprehensive financial analysis. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a voting result announcement. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and investment activities.
2023-04-04 Chinese
关于使用部分闲置募集资金购买结构性存款到期赎回并继续购买结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Henan Xintiandi Pharmaceutical Co., Ltd. regarding the use of part of idle raised funds to purchase structured deposits and continue purchasing structured deposits. It details the amounts, banks, product types, expected yields, and risk control measures. The document is relatively short (2361 characters) and focuses on a specific financing activity related to the use of idle raised funds for cash management and investment products. There is no indication of comprehensive financial statements, quarterly or annual results, or management discussion of financial performance. The content fits the category of updates on company fundraising or capital structure changes, specifically the use of raised funds for investment products. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2023-04-04 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.